Skip to main content
. Author manuscript; available in PMC: 2024 Jul 9.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2024 Jan 9;33(1):158–169. doi: 10.1158/1055-9965.EPI-23-0262

Table 1.

Associations between KRAS mutation and covariates of interest, reported as ORs with 95% Bonferroni CIs (corrected over all tested covariates), and effects of having a KRAS mutation on survival in each subgroup, reported as HRs with 95% Bonferroni CIs (corrected within each category of covariates), in the NSCLC cohort. Only Stage IV adenocarcinomas are considered in quantities reported below the horizontal line.

KRAS OR (Association with mutation occurrence and each covariate) KRAS HR (Association with survival within each subgroup)

Stage 1
 Stage I Referent 0.85 (0.44, 1.63)
 Stage II 1.05 (0.56, 1.91) 1.43 (0.70, 2.90)
 Stage III 0.77 (0.46, 1.27) 0.94 (0.58, 1.53)
 Stage IV 0.81 (0.54, 1.23) 1.44 (1.10, 1.90)
Histology 2
 Squamous cell Referent 0.86 (0.30, 2.46)
 Adenocarcinoma 9.67 (3.89, 31.83) 1.39 (1.11, 1.75)
 Other 7.51 (2.59, 27.05) 0.87 (0.48, 1.57)

Institution 1
 MSK Referent 1.72 (1.13, 2.61)
 DFCI 1.38 (0.73, 2.60) 1.63 (0.97, 2.73)
 VICC 1.43 (0.64, 3.12) 1.62 (0.88, 2.98)
Sex 3
 Male Referent 1.71 (1.09, 2.67)
 Female 1.55 (0.86, 2.86) 1.55 (1.11, 2.16)
Age (years) 4 1.04 (1.01, 1.07)
Race 1
 White Referent 1.51 (1.11, 2.06)
 Asian 0.12 (0.01, 0.53) 0.96 (0.14, 6.73)
 Black 1.09 (0.28, 3.64) 25.91 (1.55, 433.56)
 Other 0.51 (0.02, 3.69) 2.57 (0.04, 157.78)
Smoking History 1
 Never Referent 0.98 (0.30, 3.19)
 Ever 11.70 (4.52, 39.47) 1.43 (1.07, 1.91)
1

Age at diagnosis and sex included in the model.

2

Age at diagnosis, sex, and stage at diagnosis included in the model.

3

Age at diagnosis included in the model.

4

Sex included in the model.